Products

Our pipeline: Delivering first-in-class immunotherapies of activation and regulation

 

Complementary Platforms and Balanced Pipeline

  • Immuno-Oncology
  • Immuno-Inflammation
Product
Mono/Combo
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Mono
NSCLC post-ICI
+ Opdivo®
NSCLC post-ICI
+ Keytruda®
Ovarian maintenance
+ Chemo
Pancreatic maintenance
+ Ezabenlimab
MSS Endometrial, MSS CRC
BI 765063 (SIRPa antagonist)
+ Ezabenlimab + Erbitux/chemo/BI 836880
HNSCC (2L) / HCC (1L/2L) - BI
Various cancers
Various cancers
Ulcerative colitis, Sjögren's syndrome
Kydney transplant
Auto-immune diseases
COVID-19 Immunocompromised patients

Significant partnerships with Servier, Boehringer Ingelheim and Veloxis Pharmaceuticals for up to €1.6Bn in milestones (€95 M already received since 2016)

The 3 areas of expertise

Three areas of expertise are being developed within our immunology research platform:

  • T-cell based vaccination
  • Immuno-Oncology (focus on myeloid targets)
  • Auto-Immunity & Inflammation

To receive OSE Immunotherapeutics’ latest news